Skip to main content

Profile: Bin Guo

Bin Guo
Bin Guo, Ph.D.
Associate Professor of Pharmaceutics
Department of Pharmacological and Pharmaceutical Sciences
Health Building 2,
4849 Calhoun Road, Room 7046,
Houston, TX 77204-5037

832-842-8301
bguo3@uh.edu

Education

Ph.D. in Molecular Pharmacology, Roswell Park Cancer Institute, Department of Molecular Pharmacology and Cancer Therapeutics, Graduate Division of State University of New York (SUNY) at Buffalo, Buffalo, NY

B.S. in Cell Biology, Department of Biology, The University of Science and Technology of China, Hefei, P.R. China

Research Interests

Understanding the epigenetic mechanisms that regulate cancer progression and the development of new cancer therapeutic agents

Patents

"Methods for Identifying Modulators of Apoptosis". United States patent number: 435/7.2; 424/9.2. International patent number G01N 033/53; G01N 033/567; G01N 033/574; A61K 049/00.

"Conversion of Apoptotic Proteins". United States patent number 514/12; 424/155.1; 530/350; 530/388.8. International patent number A61K 039/395; A61K 038/17.

Memberships, Editorial Appointments and Service Activities

Memberships

  • Kappa Chapter, The Rho Chi Society (Pharmaceutical Honor Society)
  • American Association of Colleges of Pharmacy (AACP)
  • American Association for Cancer research (AACR)
  • American Association for the Advancement of Science (AAAS)

Editorial Appointments

  • Associate Editor, American Journal of Cancer Research
  • Editor, Journal of Cancer Therapeutics and Research
  • Editor, Clinical Pharmacology & Biopharmaceutics
  • Manuscript Reviewer: Journal of Biological Chemistry; Cancer Research; Molecular Biology of the Cell; Cancer Prevention Research; Oncogene; Journal of Gastroenterology; Cancer Letter; Clinical Biochemistry; British Journal of Cancer; PLOS ONE; Journal of Molecular Medicine; Experimental Cell Research

Service Activities

  • Member of NIH ZRG1 OBT-A (55) R study section, November 2016
  • Member of NIH F09B_2016_05 CSR Fellowship Panel, March 2016
  • Member of NIH GDD (gene and drug delivery) study section, October, 2015
  • Department of Veterans Affairs, VA Oncology Merit Review Panel (ONCA), 2015
  • Department of Veterans Affairs, VA Oncology Merit Review Panel (ONCA), 2014
  • Department of Veterans Affairs, VA Oncology Merit Review Panel (ONCA), 2013
  • National Institute of Health, R15 study section, Internet Assisted Review, 2012
  • National Medical Research Council, Singapore, 2011
  • Member of study section for Concept Award - Cell Biology, DOD BCRP, 2010
  • Mail Reviewer, NIH/NCI study section (CAMP), 2009
  • Member of Cell Biology study section CBY#1, Department of Defense Breast Cancer Research Program, 2006, 2009
  • Israel Science Foundation, 2005

Research Support

Active Grants

Title: Center for Diagnostic and Therapeutic Strategies in Pancreatic Cancer (P20 GM109024-01A1)
Source: National Institutes of Health/National Institute of General Medical Sciences
Role: Director of Animal Core
Dates:03/01/16 – 02/28/21

Title: RNA Therapeutics for Targeted Treatment of Colon Cancer (R01 CA186100-01A1)
Source: National Institutes of Health/National Cancer Institute
Role: Principal Investigator
Dates: 5/19/2015–4/30/2019
Total Costs: $1,351,550

Title: Echogenic Polymersomes for Triggered Contents Release (R01 GM114080-01)
Source: National Institutes of Health/National Institute of General Medical Sciences
Role: Multi-Principal Investigator
Dates: 9/5/15–8/31/19
Total Costs: $1,161,750

Completed Research Support

Title: Center for Protease Research (P30 GM103332)
Source: National Institutes of Health/National Institute of General Medical Sciences
Role: Project Principal Investigator
Dates: 7/1/14–6/30/16

Title: New Strategies for Targeting Protease in Disease (P20 RR015566)
Source: NIH/NCRR
Role: Project Principal Investigator
Dates: 7/01/07–6/30/13

Title: Mechanism of Bax activation in apoptosis (R21 CA111765)
Source: National Institutes of Health/National Cancer Institute
Role: Principal Investigator
Dates: 9/01/05–8/31/08

Title: A Novel Membrane-Permeable, Breast-Targeting, Pro-Apoptotic Peptide for Treatment of Breast Cancer
Source: Department of Defense BCRP (W81XWH-04-1-0705)
Role: Principal Investigator
Dates: 9/30/04–9/30/06

Title: Chemoprevention of Familial Adenomatous Polyposis by a Combination of 3,3’-Diindolylmethane and Butyrate in APCmin/+ Mice (R03 CA130062)
Source: National Institutes of Health/National Cancer Institute
Role: Principal Investigator
Dates: 7/01/08–6/30/11

Selected Publications (since 2006)

Pi F., Binzel DW, Lee TJ, Li Z., Sun M., Rychahou P., Li H., Haque F., Wang S., Croce CM, Guo B., Evers BM, Guo P. Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression. Nature Nanotechnology 2017. doi: 10.1038/s41565-017-0012-z.

Sun M. and Guo B. 2017 Vitamin D and the epigenetic machinery in colon cancer. Current Medicinal Chemistry, 24(9): 888-897.

Sun M., Zhang Q., Yang X., Qian S., and Guo B. 2016 Vitamin D enhances the efficacy of irinotecan through miR-627-mediated inhibition of intratumoral drug metabolism Molecular Cancer Therapeutics 15(9): 2086-95.

Raza S., Meyer M., Goodyear C., Hammer K., Guo B., and Ghribi O. 2017 The cholesterol metabolite 27-hydroxycholesterol stimulates cell proliferation via ERβ in prostate cancer cells. Cancer Cell International, 17:52 doi: 10.1186/s12935-017-0422-x.

Yang X., Xu Y., Brooks A., Guo B., Miskimins K., Qian S. 2016 Knockdown delta-5-desaturase promotes the formation of a novel free radical byproduct from COX-catalyzed ω-6 peroxidation to induce apoptosis and sensitize pancreatic cancer cells to chemotherapy drugs Free Radical Biology and Medicine, 97, 342-50.

Karandish F., Haldar M., You S., Brooks A., Brooks B., Guo B., Choi Y., Mallik S. 2016 Prostate-specific membrane antigen targeted polymersomes for delivering mocetinostat and docetaxel to prostate cancer cell spheroids ACS Omega, 1, 952-962.

Zhang Q., Sun M., Zhou S., and Guo B. 2016 Class I HDAC inhibitor mocetinostat induces apoptosis by activation of miR-31 expression and suppression of E2F6 Cell Death Discovery, 2:36, doi:10.1038/cddiscovery.2016.36.

Binzel DW, Shu Y., Li, H., Sun M., Zhang Q., Shu D., Guo B., and Guo P. 2016 Specific delivery of miRNA for high efficient inhibition of prostate cancer by RNA nanotechnology. Molecular Therapy 24(7): 1267–1277.

Xu Y., Yang X., Zhao P., Yang Z., Yan C., Guo B., Qian SY 2016 Knockdown of delta-5-desaturase promotes the anti-cancer activity of dihomo-γ-linolenic acid and enhances the efficacy of chemotherapy in colon cancer cells expressing COX-2. Free Radical Biology and Medicine, 96: 67-77.

Raza S., Meyer M., Schommer J., Hammer K., Guo B., and Ghribi O. 2016 27-Hydroxycholesterol stimulates cell proliferation and resistance to docetaxel-induced apoptosis in prostate epithelial cells. Medical Oncology 33 (2):12.

Zhang Q., Padi KR S., Tindall DJ, and Guo B. 2014 Polycomb protein EZH2 suppresses apoptosis by silencing the pro-apoptotic miR-31. Cell Death and Disease, 5, e1486; doi:10.1038/cddis.2014.454.

Singh R. K., Cho K., Padi S.K.R., Yu J., Halder M., Mandal T., Yan C., Cook G., Guo B., Mallik S., and Srivastava D.K. 2015 Mechanism of N-acylthiourea Mediated Activation of Human Histone Deacetylase 8 (HDAC8) at Molecular and Cellular Levels. Journal of Biological chemistry, 290(10): 6607-19.

Kulkarni P.S., Haldar M.K., Nahire R.R., Katti P., Ambre A.H., Muhonen W.W., Shabb J.B., Padi S.K., Singh R.K., Borowicz P.P., Shrivastava D.K., Katti K.S., Reindl K., Guo B., Mallik S. 2014 MMP-9 responsive PEG cleavable nanovesicles for efficient delivery of chemotherapeutics to pancreatic cancer. Molecular Pharmaceutics, 11(7): 2390-9.

Padi KR S., Zhang Q., Rustum YM, Morrison C., and Guo B. 2013 MicroRNA-627 mediates the epigenetic mechanism of vitamin D to suppress proliferation of human colorectal cancer cells and growth of xenograft tumors in mice. Gastroenterology, 145(2): 437-46. Impact Factor: 18.392

Guo B., Binzel D.W. 2013 MicroRNAs: Biology and Role in RNA Nanotechnolgy. In P. Guo & F. Haque (Eds.), RNA Nanotechnology and Therapeutics (pp. 533-41). Boca Raton, FL: CRC Press.

Bhatnagar N., Li X., Padi KR S., Zhang Q., Tang M., and Guo B. 2010 Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death and Disease, 1, e105; doi:10.1038/cddis.2010.85.

Li Y., Li X., and Guo B. 2010 Chemopreventive agent 3,3’-Diindolylmethane selectively induces proteasomal degradation of class I histone deacetylases. Cancer Research, 70(2): 646-54.

Scott M.D., Dutta R., Haldar M.K., Guo B., Friesner D.L., and Mallik S. 2012 Differentiation of prostate cancer cells using flexible fluorescent polymers. Analytical Chemistry, 84, 17-20.

Bhatnagar N., Li X., Chen Y., Zhou X., Garrett SH, and Guo B. 2009 3,3’-Diindolylmethane enhances the efficacy of butyrate in colon cancer prevention through down-regulation of survivin. Cancer Prevention Research, 2(6): 581-589.

Huang X., Li X., and Guo B. 2008 KLF6 induces apoptosis in prostate cancer cells through up-regulation of ATF3. Journal of Biological chemistry, 283(44):29795-801.

Huang X. and Guo B. 2006 Adenomatous polyposis coli Determines Sensitivity to Histone Deacetylase Inhibitor-Induced Apoptosis in Colon Cancer Cells. Cancer Research, 66(18):9245-51.

Invited Lectures

  • "miR-627 and Vitamin D in Colon Cancer Suppression." Epigenetics and Epigenomics Symposium, University of North Dakota, Grand Forks, ND, Oct. 2, 2014.
  • "Epigenetic Regulation of Apoptosis in Cancer Treatment and Prevention." Mayo Clinic, Rochester, MN, Aug 9, 2010.
  • "Epigenetic Regulation of Apoptosis." New York University School of Medicine, New York, NY, Nov 11, 2009.

Awards and Honors

  • The Dean's Award for Excellence in Research, NDSU College of Pharmacy, 2016
  • The Dean’s Award for Excellence in Research, NDSU College of Pharmacy, 2010
  • Who’s Who in America, 2009 Edition.